Condition: Pancreatic Adenocarcinoma Locally Advanced · Sponsor: Ruijin Hospital
The study explores the efficacy and safety of irreversible electroporation(IRE) combined with the dual-function antibody PD-1/CTLA-4 (Apalulizumab) for the treatment of locally advanced pancreatic cancer following failure of first-line AG therapy. This research aims to accumulate more clinical evidence and treatment options for second-line therapy in locally advanced pancreatic cancer following failure of first-line regimen.
This description comes directly from the study's public registry record.
Zhongmin Wang, Doctor · 0086-13901848333 · wzm11896@rjh.com.cn
Jingfeng Li, Doctor · 0086-13918536451 · 13918536451@163.com
Always discuss trial participation with your own doctor first.
| Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07306273